

SELL

TP: Rs 551 | ▼ 10%

JK LAKSHMI CEMENT

Cement

01 August 2023

Another slow quarter; maintain SELL

- Tepid volume growth of 5% YoY with little support from realisations kept Q1 revenue growth muted
- EBITDA margin dropped 370bps YoY to 10% as costs spiralled and realisations remained under pressure
- Retain SELL with an unchanged TP of Rs 551

Milind Raginwar

research@bobcaps.in

Topline growth muted: JKLC reported slow 5% YoY (-6% QoQ) revenue growth to Rs 16.3bn in Q1FY24 as volumes grew only 5% (-5% QoQ) to 2.9mn tonnes (including clinker sales) and realisations stayed flat at Rs 5,351/t (-1% QoQ). Key markets such as Gujarat and Rajasthan saw adverse weather impacts and labour shortages in Q1 even as excess supply exerted pressure on prices.

Cost inflation continues, to turn favourable from H2: Operating cost increased 5% YoY (flat QoQ) to Rs 5,011/t as energy-adjusted raw material cost climbed 4% YoY to Rs 2,210/t on a higher base. Limited in-house clinker prompted higher I purchases from UCWL (+29% YoY). Logistics cost inched up 1% YoY to Rs 1,130/t due to the railway's introduction of a busy period surcharge for the entire year.

Margins dented: EBITDA declined 23% YoY (-11% QoQ) to Rs 1.7bn with 370bps contraction in margin to 10.3% due to the high-cost structure and tepid realisations. EBITDA/t decreased 26% YoY (-7% QoQ) to Rs 573/t and PAT dropped 26% YoY (-23% QoQ) to Rs 749mn. Management has set an ambitious EBITDA/t target of Rs 1,000 for FY25.

Expansion plans: Subsidiary UCWL's 1.5mt clinker unit is to be commissioned by Q3FY24 and its 2.5mt cement plant expansion by Q2FY25. Both projects are on track with trial runs of the clinker unit underway. JKLC aims to reach 18mt with the UCWL expansion and 30mt in phase II (via 3mt of brownfield expansion at Durg (Chhattisgarh) and 3mt at Udaipur (Rajasthan), along with 6mt of greenfield capacity, for which it has been allocated two mines in Nagaur (Rajasthan) and Kutch (Gujarat).

Maintain SELL: JKLC plans to fund its capex through debt and has passed an enabling resolution to raise borrowings of Rs 25bn. This will take the net debt/EBITDA ratio to a peak of 4x, per management. We also expect margins to remain stressed given fierce competition in key markets. Factoring in these negatives, we maintain SELL and continue to value the stock at 8x FY25E EV/EBITDA for a TP of Rs 551 (unchanged). Our TP implies a replacement cost of Rs 6.6bn/mt, a 6% discount to the industry benchmark.

Key changes

Target	Rating
◀ ▶	◀ ▶

Ticker/Price	JKLC IN/Rs 609
Market cap	US\$ 872.9mn
Free float	54%
3M ADV	US\$ 2.4mn
52wk high/low	Rs 897/Rs 439
Promoter/FPI/DII	46%/14%/26%


Source: NSE | Price as of 31 Jul 2023

Key financials

Y/E 31 Mar	FY23P	FY24E	FY25E
Total revenue (Rs mn)	60,711	67,356	73,729
EBITDA (Rs mn)	7,043	7,860	9,558
Adj. net profit (Rs mn)	3,307	3,876	4,708
Adj. EPS (Rs)	28.1	32.9	40.0
Consensus EPS (Rs)	28.1	44.2	51.1
Adj. ROAE (%)	12.8	13.4	14.4
Adj. P/E (x)	21.7	18.5	15.2
EV/EBITDA (x)	10.2	9.5	8.7
Adj. EPS growth (%)	(26.5)	17.2	21.5

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

Stock performance



Source: NSE



Fig 1 – Earnings call highlights

Parameter	Q1FY24	Q4FY23	Our view
Volumes and Realisations	<p>Management indicated that Q1 was impacted by natural calamities and labour shortages in Gujarat and Rajasthan (accounting for 70% sales). JKLC had 97% clinker utilisation and 85% cement utilisation during the quarter.</p> <p>The company expects eastern market volumes to improve as it has received approval for a rail siding and conveyor belt at the Durg plant. Realisations were flat despite tepid volume growth.</p>	<p>Management expects cement volume growth of 19% for FY24. The clinker plant (1.5mt) is to be used for grinding units in the north to aid volume growth. Capacity utilisation stood at 89% in Q4FY23 vs. 77% in Q3FY23.</p> <p>Pricing pressure continues and the current price has remained flat to marginally lower. Q4 trade volume share was at 55%, blended share at 55%, and premium share at 11%.</p>	JKLC will likely face severe competition to volume growth in key regions, including the west, north and east.
Margins	<p>Power and fuel costs declined QoQ from Rs 2.42/kcal to Rs 2.23/kcal, but operating cost was higher as a WHRS facility broke down, requiring more grid power. Logistics cost also inched up.</p> <p>Management expects energy cost to decline to Rs 2.15/kcal in Q2FY24 as JKLC holds 100-days of inventory at these low prices, in tandem with lower logistics costs. Renewable power supply is guided to increase from October, providing a Rs 2.5/unit landed price discount to grid power. All of this should aid margins.</p>	<p>Fuel cost was at Rs 2.42/kcal in Q4, which management expects will reduce to Rs 2.31/kcal in Q1FY24. The fuel mix was 40% coal (domestic in eastern markets and imported in case of the north), 44% pet coke and 16% others.</p> <p>Management has EBITDA/t targets of Rs 800/Rs 1,000 for FY24/FY25 led by a better region & product mix and shift towards trade sales, logistics cost savings (Rs 70/t) on lower lead distance, and improving efficiencies (such as enhancing the thermal substitution rate from 4% to 16% in a phased manner at its Sirohi plant).</p>	Cost benefits are likely to be negated if realisations are not supportive given severe competition from market giants such as UTCEM, ACEM and SRCM.
Capacity	<p>WHRS capacity at the Sirohi plant in Rajasthan will add 3.5MW by Q4FY24-end. The clinkerisation plant at Udaipur Cement Works (UCWL) is under trial runs and is due to add 1.5mt of capacity by Q3FY24. Further, the 2.5mt expansion at UCWL is on track to be commissioned in Q2FY25.</p>	<p>Management is currently focused on brownfield expansion at Durg and will decide on UCWL in FY25. Land acquisition activities have begun for the greenfield projects at Nagaur and Kutch.</p>	Capacity plans are necessary in the short term but look aggressive over the medium-to-long term and will only put further pressure on performance.
Capex	<p>Management has guided for an annual capex budget of Rs 3bn-4.5bn for FY24.</p>	<p>Capex incurred for UCWL totals Rs 8.5bn to date (Rs 6.3bn in FY23).</p> <p>JKLC plans to incur Rs 2bn in FY24 and Rs 1.5bn in FY25, with the outlay for UCWL at Rs 5bn and Rs 3bn respectively.</p>	Annual capex is likely to swell from FY25 onwards.
Other key points	<p>JKLC has passed an enabling resolution to raise debt of Rs 25bn to fund ongoing projects. This is guided to raise net debt-to-EBITDA (currently at 1x) to 3.5-4x in the next two years. This apart, subsidiary UCWL recently completed a ~Rs 4.5bn rights issue to finance ongoing capex.</p> <p>Non-cement revenue was Rs 1.3bn in Q1, of which RMC made up Rs 630mn. EBITDA margin on non-cement business contracted QoQ from 5% to 4%.</p> <p>JKLC entered a partnership with a private company for the supply of 40MW of solar power for its Durg cement plant. After integration, 80% of energy for Durg will be renewable and JKLC's overall renewable mix will rise to 50%.</p>	<p>JKLC aims to have peak debt of Rs 15bn for UCWL and maximum net debt/EBITDA at 3-3.5x.</p> <p>The company is setting up a 100,000t putty plant in Alwar, Rajasthan, to start operations from Oct'23 at a capex of Rs 0.65bn-0.7bn.</p> <p>For Q4FY23, non-cement revenue was at Rs 1.3bn (RMC revenue at Rs 0.6bn).</p> <p>The Palanpur (outsourced) grinding unit has capacity of 15-20k/t per month.</p>	Higher leverage at 3-4x can pose a risk.

Source: Company, BOBCAPS Research | RMC: Ready Mix Concrete; WHRS: Waste Heat Recovery System

Fig 2 – Key metrics

(Rs mn)	Q1FY24	Q1FY23	YoY (%)	Q4FY23	QoQ (%)
Volumes (mn mt)	2.93	2.79	5.0	3.06	(4.5)
Cement realisations (Rs/mt)	5,351	5,370	(0.3)	5,422	(1.3)
Operating costs (Rs/mt)	5,011	4,788	4.7	5,027	(0.3)
EBITDA/mt (Rs)	573	779	(26.4)	617	(7.2)


Source: Company, BOBCAPS Research

Fig 3 – Quarterly performance

(Rs mn)	Q1FY24	Q1FY23	YoY (%)	Q4FY23	QoQ (%)
Net Sales	16,333	15,510	5.3	17,289	(5.5)
Expenditure					
Change in stock	347	13	2,679.2	734	(52.6)
Raw material	2,409	2,270	6.1	2,351	2.5
Purchased products	2,095	1,543	35.8	2,053	2.0
Power & fuel	3,708	3,660	1.3	4,103	(9.6)
Freight	3,305	3,120	5.9	3,530	(6.4)
Employee costs	976	922	5.8	860	13.5
Other expenses	1,818	1,813	0.2	1,768	2.8
Total Operating Expenses	14,657	13,340	9.9	15,398	(4.8)
EBITDA	1,676	2,170	(22.8)	1,891	(11.4)
EBITDA margin (%)	10.3	14.0	(373bps)	10.9	(68bps)
Other Income	139	74	86.9	178	(22.0)
Interest	229	247	(7.2)	195	17.5
Depreciation	470	473	(0.7)	501	(6.2)
PBT	1,115	1,524	(26.8)	1,373	(18.8)
Non-recurring items	0	0	0.0	0	0.0
PBT (after non-recurring items)	1,115	1,524	(26.8)	1,373	(18.8)
Tax	366	515	(28.8)	400	(8.3)
Tax Rate (%)	33	34	(92bps)	29	375bps
Reported PAT	749	1,009	(25.8)	973	(23.1)
Adjusted PAT	749	1,009	(25.8)	973	(23.1)
NPM (%)	4.6	6.5	(192bps)	5.6	(104bps)
Adjusted EPS (Rs)	6.4	8.6	(25.8)	8.3	(23)


Source: Company, BOBCAPS Research

Fig 4 – Weather impact in key regions limited Q1FY24 volume growth




Source: Company, BOBCAPS Research

Fig 5 – Realisations listless




Source: Company, BOBCAPS Research

Fig 6 – EBITDA/t down 26% YoY...




Source: Company, BOBCAPS Research

Fig 7 – ...as costs remained inflated




Source: Company, BOBCAPS Research

Fig 8 – Surcharge, high fuel cost pushed up logistics cost



Source: Company, BOBCAPS Research

Fig 9 – Energy cost offers some respite



Source: Company, BOBCAPS Research

Valuation methodology

JKCL has guided for an annual capex budget of Rs 3bn-4.5bn for FY24 and expansionary capex mode from FY25 onward. The company plans to fund this outlay through debt and has passed an enabling resolution to raise borrowings of Rs 25bn. This will take the net debt/ EBITDA ratio to a peak of 4x in the next two years, per management. Not only could this pose a risk to balance sheet health, but past experience also suggests that the company's capex execution has been less than ideal, typically marred by delays (both inhouse and at subsidiary UCWL).

We also expect margins to remain stressed given fierce competition in key markets. In our view, management's EBITDA/t targets of Rs 800/Rs 1,000 for FY24/FY25 look aggressive and we instead pen in estimates of Rs 644/Rs 713.

Factoring in the negatives, we maintain our SELL rating and continue to value the stock at 8x FY25E EV/EBITDA for a TP of Rs 551 (unchanged). Our TP implies a replacement cost of Rs 6.6bn/mt, a 6% discount to the industry benchmark.

Fig 10 – Key assumptions

Parameter	FY22	FY23	FY24E	FY25E
Volumes (mt)	10.3	10.8	12.2	13.4
Realisations (Rs/mt)	4,494	5,386	5,510	5,538
Operating costs (Rs/mt)	4,132	4,951	4,877	4,789
EBITDA/mt (Rs)	781	648	644	713

Source: Company, BOBCAPS Research

Fig 11 – Valuation summary

(Rs mn)	FY25E
Target EV/EBITDA (x)	8
EBITDA	9,558
Target EV	76,466
Total EV	76,466
Net debt	11,104
Target market capitalization	65,362
Target price (Rs/sh)	551
Weighted average shares (mn)	118

Source: Company, BOBCAPS Research

Key risks

Key upside risks to our estimates are:

- above-estimated volume and realisations gains backed by strong demand uptick, and
- faster-than-expected cooling off of key fuel costs, lending a boost to margins.

Fig 12 – Peer comparison

Ticker	Rating	Target Price (Rs)	EV/EBITDA (x)			EV/tonne (US\$)			ROE (%)			ROCE (%)		
			FY23	FY24E	FY25E	FY23	FY24E	FY25E	FY23	FY24E	FY25E	FY23	FY24E	FY25E
JKLC IN	SELL	551	10.1	9.5	8.7	81	84	93	12.8	13.4	14.4	16.2	17.3	17.2
JKCE IN	BUY	3,371	20.6	16.2	11.7	156	153	150	12.6	17.3	20.4	12.4	16.6	19.8
TRCL IN	SELL	585	22.0	17.1	14.4	139	138	139	4.6	7.1	8.8	5.8	7.8	9.2

Source: Company, BOBCAPS Research

Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
ACC	ACC IN	4.6	2,018	1,964	HOLD
Ambuja Cements	ACEM IN	11.2	463	375	HOLD
Dalmia Bharat	DALBHARA IN	4.4	1,954	1,917	HOLD
JK Cement	JKCE IN	3.1	3,275	3,474	HOLD
JK Lakshmi Cement	JKLC IN	0.9	609	551	SELL
Orient Cement	ORCMNT IN	0.4	147	140	HOLD
Shree Cement	SRCM IN	10.6	24,108	24,656	HOLD
Star Cement	STRCEM IN	0.7	145	146	BUY
The Ramco Cements	TRCL IN	2.5	886	585	SELL
Ultratech Cement	UTCEN IN	29.2	8,318	9,396	HOLD

Source: BOBCAPS Research, NSE | Price as of 31 Jul 2023

Financials

Income Statement

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23P	FY24E	FY25E
Total revenue	43,847	50,408	60,711	67,356	73,729
EBITDA	7,898	8,013	7,043	7,860	9,558
Depreciation	(1,942)	(1,905)	(1,935)	(1,992)	(2,303)
EBIT	6,700	6,780	5,729	6,704	8,113
Net interest inc./(exp.)	(1,425)	(963)	(915)	(854)	(1,027)
Other inc./(exp.)	745	673	621	837	858
Exceptional items	(309)	(234)	0	0	0
EBT	4,966	5,583	4,814	5,851	7,086
Income taxes	(1,328)	(1,321)	(1,507)	(1,975)	(2,378)
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	3,638	4,262	3,307	3,876	4,708
Adjustments	309	234	0	0	0
Adjusted net profit	3,947	4,496	3,307	3,876	4,708

Balance Sheet

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23P	FY24E	FY25E
Accounts payables	10,764	7,658	13,380	14,833	15,647
Other current liabilities	6,315	7,046	1,246	7,458	7,680
Provisions	201	267	177	760	821
Debt funds	7,904	7,953	8,447	9,525	18,814
Other liabilities	641	943	1,596	170	198
Equity capital	588	588	588	588	588
Reserves & surplus	20,209	23,419	26,683	30,043	34,201
Shareholders' fund	20,797	24,523	27,267	30,632	34,790
Total liab. and equities	46,622	48,390	52,111	63,377	77,950
Cash and cash eq.	7,270	8,869	8,642	6,759	7,710
Accounts receivables	537	345	605	1,753	2,121
Inventories	3,155	4,912	7,004	7,289	8,383
Other current assets	2,932	2,003	3,738	6,547	7,202
Investments	3,833	3,899	3,948	3,998	4,049
Net fixed assets	26,371	27,134	27,210	27,416	40,359
CWIP	2,451	1,127	857	9,500	8,000
Intangible assets	72	103	108	116	127
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
Total assets	46,621	48,390	52,112	63,377	77,950

Cash Flows

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23P	FY24E	FY25E
Cash flow from operations	7,992	3,537	1,645	8,448	6,020
Capital expenditures	(1,180)	(1,386)	(1,753)	(10,849)	(13,757)
Change in investments	352	(1,867)	136	245	(1,051)
Other investing cash flows	0	0	0	0	0
Cash flow from investing	(828)	(3,253)	(1,616)	(10,604)	(14,808)
Equities issued/Others	0	516	(521)	5	0
Debt raised/repaid	(3,926)	49	494	1,079	9,289
Interest expenses	0	0	0	0	0
Dividends paid	(441)	(441)	(441)	(441)	(471)
Other financing cash flows	473	(609)	399	(74)	(79)
Cash flow from financing	(3,894)	(486)	(70)	568	8,739
Chg in cash & cash eq.	3,270	(202)	(42)	(1,588)	(48)
Closing cash & cash eq.	7,270	8,869	8,642	6,759	7,710

Per Share

Y/E 31 Mar (Rs)	FY21A	FY22A	FY23P	FY24E	FY25E
Reported EPS	30.9	36.2	28.1	32.9	40.0
Adjusted EPS	33.5	38.2	28.1	32.9	40.0
Dividend per share	3.8	3.8	3.8	3.8	4.0
Book value per share	176.7	208.4	231.7	260.3	295.6

Valuations Ratios

Y/E 31 Mar (x)	FY21A	FY22A	FY23P	FY24E	FY25E
EV/Sales	1.7	1.4	1.2	1.1	1.1
EV/EBITDA	9.2	8.8	10.2	9.5	8.7
Adjusted P/E	18.2	16.0	21.7	18.5	15.2
P/BV	3.4	2.9	2.6	2.3	2.1

DuPont Analysis

Y/E 31 Mar (%)	FY21A	FY22A	FY23P	FY24E	FY25E
Tax burden (Net profit/PBT)	73.3	76.3	68.7	66.2	66.4
Interest burden (PBT/EBIT)	78.7	85.8	84.0	87.3	87.3
EBIT margin (EBIT/Revenue)	15.3	13.5	9.4	10.0	11.0
Asset turnover (Rev./Avg TA)	95.2	106.1	120.8	116.6	104.3
Leverage (Avg TA/Avg Equity)	2.4	2.1	1.9	2.0	2.2
Adjusted ROAE	20.4	19.6	12.8	13.4	14.4

Ratio Analysis

Y/E 31 Mar	FY21A	FY22A	FY23P	FY24E	FY25E
YoY growth (%)					
Revenue	8.4	15.0	20.4	10.9	9.5
EBITDA	17.5	1.5	(12.1)	11.6	21.6
Adjusted EPS	48.7	13.9	(26.5)	17.2	21.5
Profitability & Return ratios (%)					
EBITDA margin	18.0	15.9	11.6	11.7	13.0
EBIT margin	15.3	13.5	9.4	10.0	11.0
Adjusted profit margin	9.0	8.9	5.4	5.8	6.4
Adjusted ROAE	20.4	19.6	12.8	13.4	14.4
ROCE	22.9	21.6	16.2	17.3	17.2
Working capital days (days)					
Receivables	4	2	4	10	11
Inventory	26	36	42	40	42
Payables	109	66	91	91	89
Ratios (x)					
Gross asset turnover	1.2	1.3	1.5	1.5	1.2
Current ratio	0.8	1.1	1.4	1.0	1.1
Net interest coverage ratio	4.7	7.0	6.3	7.9	7.9
Adjusted debt/equity	0.4	0.3	0.3	0.3	0.5

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): JK LAKSHMI CEMENT (JKLC IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS’s prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS’s associates may have financial interest in the subject company. BOBCAPS’s associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an “as is” basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS’s judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the “Losses”) which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom (“UK”):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd (“MSL”) who is authorised and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom (MSL and its affiliates are collectively referred to as “MAYBANK”). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK’s legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the “Order”), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as “relevant persons”).

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.